Martin Kummen

Martin Kummen

Auto-generated profile, based on publicly available information

Martin Kummen

Norwegian PSC Research Center, Oslo University Hospital, Rikshospitalet, Oslo, Norway

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JWJun Wang
Jun Wang
LTLouise B Thingholm
Louise B Thingholm
JSJurgita Skiecevičienė
Jurgita Skiecevičienė
PRPhilipp Rausch
Philipp Rausch
MKMartin Kummen
Martin Kummen
AFAndre Franke
Andre Franke
Andre Franke and colleagues perform a genome-wide association study for the gut microbiome, examining the influence of host genetics on overall microbial variation and individual taxa. They find significant associations at the VDR (vitamin D receptor) locus and observe correlations between microbiota and metabolites of VDR, including bile acids. Human gut microbiota is an important determinant for health and disease, and recent studies emphasize the numerous factors shaping its diversity. Here we performed a genome-wide association study (GWAS) of the gut microbiota using two cohorts from northern Germany totaling 1,812 individuals. Comprehensively controlling for diet and non-genetic parameters, we identify genome-wide significant associations for overall microbial variation and individual taxa at multiple genetic loci, including the VDR gene (encoding vitamin D receptor). We observe significant shifts in the microbiota of Vdr−/− mice relative to control mice and correlations between the microbiota and serum measurements of selected bile and fatty acids in humans, including known ligands and downstream metabolites of VDR. Genome-wide significant (P < 5 × 10−8) associations at multiple additional loci identify other important points of host–microbe intersection, notably several disease susceptibility genes and sterol metabolism pathway components. Non-genetic and genetic factors each account for approximately 10% of the variation in gut microbiota, whereby individual effects are relatively small.

17 February 2016 in Gut
Verified
Journal Article
Closed access
PDF file
MKMartin Kummen
Martin Kummen
KHKristian Holm
Kristian Holm
JAJarl Andreas Anmarkrud
Jarl Andreas Anmarkrud
Ståle NygårdStåle Nygård
Ståle Nygård
MVMette Vesterhus
Mette Vesterhus
JHJohannes R Hov
Johannes R Hov
Objective: Gut microbiota could influence gut, as well as hepatic and biliary immune responses. We therefore thoroughly characterised the gut microbiota in primary sclerosing cholangitis (PSC) compared with healthy controls (HC) and patients with ulcerative colitis without liver disease. Design: We prospectively collected 543 stool samples. After a stringent exclusion process, bacterial DNA was submitted for 16S rRNA gene sequencing. PSC and HC were randomised to an exploration panel or a validation panel, and only significant results (p<0.05, Q FDR <0.20) in both panels were reported, followed by a combined comparison of all samples against UC. Results: Patients with PSC (N=85) had markedly reduced bacterial diversity compared with HC (N=263, p<0.0001), and a different global microbial composition compared with both HC (p<0.001) and UC (N=36, p<0.01). The microbiota of patients with PSC with and without IBD was similar. Twelve genera separated PSC and HC, out of which 11 were reduced in PSC. However, the Veillonella genus showed a marked increase in PSC compared with both HC (p<0.0001) and UC (p<0.02). Using receiver operating characteristic analysis, Veillonella abundance yielded an area under the curve (AUC) of 0.64 to discriminate PSC from HC, while a combination of PSC-associated genera yielded an AUC of 0.78. Conclusions: Patients with PSC exhibited a gut microbial signature distinct from both HC and UC without liver disease, but similar in PSC with and without IBD. The Veillonella genus, which is also associated with other chronic inflammatory and fibrotic conditions, was enriched in PSC.

1 March 2018 in JACC
Verified
Journal Article
Closed access
MKMartin Kummen
Martin Kummen
CMCristiane C.K. Mayerhofer
Cristiane C.K. Mayerhofer
BVBeate Vestad
Beate Vestad
KBKaspar Broch
Kaspar Broch
AAAyodeji Awoyemi
Ayodeji Awoyemi
MTMarius Trøseid
Marius Trøseid

16 March 2016 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
SJS.F. Jørgensen
S.F. Jørgensen
MTM. Trøseid
M. Trøseid
MKM. Kummen
M. Kummen
JAJ.A. Anmarkrud
J.A. Anmarkrud
AMA.E. Michelsen
A.E. Michelsen
JHJ.R. Hov
J.R. Hov
Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency characterized by low immunoglobulin (Ig)G and IgA, and/or IgM. In addition to bacterial infections, a large subgroup has noninfectious inflammatory and autoimmune complications. We performed 16S ribosomal RNA-based profiling of stool samples in 44 CVID patients, 45 patients with inflammatory bowel disease (disease controls), and 263 healthy controls. We measured plasma lipopolysaccharide (LPS) and markers of immune cell activation (i.e., soluble (s) CD14 and sCD25) in an expanded cohort of 104 patients with CVID and in 30 healthy controls. We found a large shift in the microbiota of CVID patients characterized by a reduced within-individual bacterial diversity (alpha diversity, P<0.001) without obvious associations to antibiotics use. Plasma levels of both LPS (P=0.001) and sCD25 (P<0.0001) were elevated in CVID, correlating negatively with alpha diversity and positively with a dysbiosis index calculated from the taxonomic profile. Low alpha diversity and high dysbiosis index, LPS, and immune markers were most pronounced in the subgroup with inflammatory and autoimmune complications. Low level of IgA was associated with decreased alpha diversity, but not independently from sCD25 and LPS. Our findings suggest a link between immunodeficiency, systemic immune activation, LPS, and altered gut microbiota.

15 June 2022 in Gut
Verified
Journal Article
Open access
PDF file
MAMuyiwa Awoniyi
Muyiwa Awoniyi
JWJeremy Wang
Jeremy Wang
BNBilly Ngo
Billy Ngo
VMVik Meadows
Vik Meadows
JTJason Tam
Jason Tam
RSRyan Balfour Sartor
Ryan Balfour Sartor
Objective: Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and experimental models. Goal: define the function of complex resident microbes and their association relevant to PSC patients by studying germ-free (GF) and antibiotic-treated specific pathogen-free (SPF) multidrug-resistant 2 deficient ( mdr2 −/− ) mice and microbial profiles in PSC patient cohorts. Design: We measured weights, liver enzymes, RNA expression, histological, immunohistochemical and fibrotic biochemical parameters, faecal 16S rRNA gene profiling and metabolomic endpoints in gnotobiotic and antibiotic-treated SPF mdr2 −/− mice and targeted metagenomic analysis in PSC patients. Results: GF mdr2 −/− mice had 100% mortality by 8 weeks with increasing hepatic bile acid (BA) accumulation and cholestasis. Early SPF autologous stool transplantation rescued liver-related mortality. Inhibition of ileal BA transport attenuated antibiotic-accelerated liver disease and decreased total serum and hepatic BAs. Depletion of vancomycin-sensitive microbiota exaggerated hepatobiliary disease. Vancomycin selectively decreased Lachnospiraceae and short-chain fatty acids (SCFAs) but expanded Enterococcus and Enterobacteriaceae. Antibiotics increased Enterococcus faecalis and Escherichia coli liver translocation. Colonisation of GF mdr2 −/− mice with translocated E. faecalis and E. coli strains accelerated hepatobiliary inflammation and mortality. Lachnospiraceae colonisation of antibiotic pretreated mdr2 −/− mice reduced liver fibrosis, inflammation and translocation of pathobionts, and SCFA-producing Lachnospiraceae and purified SCFA decreased fibrosis. Faecal Lachnospiraceae negatively associated, and E. faecalis/ Enterobacteriaceae positively associated, with PSC patients’ clinical severity by Mayo risk scores. Conclusions: We identified novel functionally protective and detrimental resident bacterial species in mdr2 −/− mice and PSC patients with associated clinical risk score. These insights may guide personalised targeted therapeutic interventions in PSC patients.

1 April 2016 in Atherosclerosis
Verified
Journal Article
Closed access
KSKarolina Skagen
Karolina Skagen
MTMarius Trøseid
Marius Trøseid
TUThor Ueland
Thor Ueland
SHSverre Holm
Sverre Holm
AAAzhar Abbas
Azhar Abbas
MSMona Skjelland
Mona Skjelland